뉴스필드

노동·인권 전문지

English Edition

Controversy Over ‘Massive Share Dumping’ by KB Fund with Kookmin Bank as Largest Investor on Baropharm’s Listing Day…Stock Plunges 65%

English translation of the original Korean report. Images and source documents may contain Korean text.

바로팜의 주가가 코스닥 상장 첫날인 11월 11일 1만1780원에서 20일 5610원으로 하락했다. 이는 확정 공모가 1만6400원 대비 65.79% 떨어진 수준이다. (자료=공개 시세·바로팜 공모자료, 그래픽=뉴스필드)
Baropharm’s share price fell from 11,780 won on November 11, its first day of trading on the KOSDAQ market, to 5,610 won on the 20th. This represents a decline of 65.79% from its final IPO price of 16,400 won. (Sources: Public market price data and Baropharm IPO materials; Graphic: Newsfield)

Two KB Financial Group-Affiliated Funds Sell 691,670 Shares on Listing Day…Sale Proceeds Total 9,284,180,000 Won

KB Kookmin Bank Holds 46.6% Stake in Fund; KB Investment Is Wholly Owned Subsidiary of KB Financial Group…Additional Shares Eligible for Sale in December as Retail Investor Anxiety Spreads

(Newsfield) As shares of pharmacy platform company Baropharm plunged more than 65% below their IPO price within eight trading days of its KOSDAQ listing, it has been confirmed that investment funds affiliated with KB Financial Group sold half of their holdings on the first day of trading. In particular, a fund in which KB Kookmin Bank is the largest investor also sold a substantial portion of its stake, drawing attention to KB Financial Group’s investment recovery strategy, given its emphasis on mutual growth with digital companies.

According to Korea Exchange market data on the 20th, Baropharm closed at 5,610 won, down 13.96% from the previous trading day. Since its KOSDAQ listing on the 11th at an IPO price of 16,400 won, the stock has fallen by 10,790 won, representing a 65.79% decline from the offering price.

According to a report on large shareholdings submitted to the Financial Supervisory Service’s electronic disclosure system on the 18th, the KB Digital Platform Fund and KB Global Platform Fund, both managed by KB Investment, sold a combined 691,670 shares on the exchange on the 11th, Baropharm’s listing day. The two funds held a total of 1,383,341 shares at the time of listing and disposed of virtually half of those holdings on the first day.

The KB Digital Platform Fund sold 257,834 of its 515,668 shares at 13,394 won per share. According to the disclosure, the fund’s largest investor is KB Kookmin Bank, which holds a 46.6% stake, and the sale proceeds are calculated at 3,453,428,596 won.

The KB Global Platform Fund also sold 433,836 of its 867,673 shares at 13,440 won per share. The sale proceeds amounted to 5,830,755,840 won, while the fund’s largest investor is KB Investment, which holds a 50% stake.

The combined proceeds from the two funds’ share sales amounted to 9,284,184,436 won. Although KB Investment is a wholly owned subsidiary of KB Financial Group, the sellers in these transactions were the individual investment funds. Therefore, the entire proceeds cannot be treated as direct profits earned by KB Financial Group or KB Kookmin Bank.

■ KB Financial Group Promoted ‘Mutual Growth with Digital Companies’…Fund Sells Half Its Holdings on First Trading Day

In December 2021, KB Financial Group established the 300 billion won ‘KB Digital Platform Fund,’ promoting mutual growth with promising companies. However, during Baropharm’s listing, a fund in which Kookmin Bank is the largest investor sold half of its holdings on the first day of trading, raising questions about whether greater priority was given to recovering investment capital than to supporting corporate growth.

Additional shares also remain eligible for sale. The two KB-affiliated funds retain 691,671 shares, while another 3,244,703 shares held by existing shareholders will be released from lock-up restrictions on December 11. As a result, 57.45% of the company’s total shares will become available for trading, although whether those shares will actually be sold has not been determined.

Retail IPO subscribers also began selling back their shares on the first day of trading. According to a disclosure filed on the 18th, Mirae Asset Securities purchased 34,685 shares at 14,760 won per share following investors’ exercise of their put-back rights. This represented 7.79% of all shares allocated to retail subscribers.

A put-back right allows investors who received shares through an IPO allocation and have continued to hold them to sell those shares back to the lead underwriter under certain conditions. The right can be exercised until February 11 of next year, and the reference price is 14,760 won, equivalent to 90% of the IPO price, although it may be adjusted depending on market conditions. Investors who purchased shares after the listing cannot exercise this right.

Anxiety was also evident in online investment communities. Comments on Baropharm-related posts included ‘IPO stocks have been having a really rough run’ and ‘Are they pulling out right after the listing..?’ Some investors expressed concerns about further declines and advised caution when buying shares. However, these reactions do not represent the views of all shareholders.

Baropharm was unable to avoid a sharp decline in its share price despite reporting approximately 49,600,000,000 won in third-quarter revenue and approximately 2,300,000,000 won in operating profit this year, marking a turnaround to profitability. Public disclosures do not establish the extent to which the KB-affiliated funds’ share sales affected the stock price, the funds’ actual investment returns, or whether KB Financial Group was involved in the decision to sell the shares.

ESC 또는 배경 클릭하여 닫기